More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...
Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results